Assembly Biosciences (ASMB)
(Delayed Data from NSDQ)
$19.40 USD
+1.00 (5.43%)
Updated Aug 4, 2025 04:00 PM ET
After-Market: $19.45 +0.05 (0.26%) 6:40 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Dividend Yield (TTM)
Assembly Biosciences, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Generic Drugs industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
ASMB 19.40 +1.00(5.43%)
Will ASMB be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ASMB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ASMB
Assembly Biosciences (ASMB) Reports Q1 Loss, Tops Revenue Estimates
Amphastar Pharmaceuticals (AMPH) Tops Q1 Earnings Estimates
ASMB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Assembly Biosciences (ASMB) Soars 24.0%: Is Further Upside Left in the Stock?
BridgeBio Pharma (BBIO) Reports Q1 Loss, Tops Revenue Estimates
Down -22.6% in 4 Weeks, Here's Why Assembly Biosciences (ASMB) Looks Ripe for a Turnaround
Other News for ASMB
Assembly Biosciences (ASMB) Showcases Promising Herpes Treatment Data
Assembly Biosciences presents Phase 1a data for ABI-5366, ABI-1179
Assembly Biosciences presents Phase 1a data for ABI-5366, ABI-1179
Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & ...
Assembly announces first participant dosed in Phase 1b trial of ABI-1179